Journal of Endocrinological Investigation

, Volume 30, Issue 5, pp 404–410 | Cite as

Goiter rate, serum thyrotropin, thyroid autoantibodies and urinary iodine concentration in Tehranian adults before and after national salt iodization

Original Articles

Abstract

Goiter rate, serum TSH, antithyroperoxidase (TPOAb), antithyroglobulin (TgAb) antibodies, and urinary iodine concentration (UIC) were evaluated 10–11 yr prior (1983–1984) and 5–6 yr after (1999–2000) national salt iodization in Iran. Pre- and post-iodization groups consisted of 465 and 1426 adults aged ⁥20 yr, respectively, selected by random cluster sampling in Tehran province. Total, grade 1 and grade 2 goiter rates were 65.2, 53.1, and 12.1 % in 1983–1984 vs 25.2, 15.5, and 9.7% in 1999–2000 (p<0.0001). Median serum TSH was 1.5 mIU/l in 1983–1984 vs 0.8 mIU/l in 1999–2000 (p<0.0001). Median TSH also decreased in 20–29, 30–39, 40–49, 50–59, and ⁥60yr-adults in 1983–1984 vs 1999–2000 (p<0.0001). In 1983–1984, positive TPOAb and positive TgAb were detected in 3.2 and 4%, respectively, using agglutination test. Corresponding values were 12.5 and 16.8% using immunoenzymometric assay in 1999–2000. Overt and subclinical hypothyroidism was present in 0 and 32.8/1000 in 1983–1984 vs 3.5 and 21.7/1000 in 1999–2000, respectively. Overt and subclinical hyperthyroidism was detected in 4.4 and 4.4/1000 in 1983–1984 vs 0.7 and 5.6/1000 in 1999–2000, respectively. Subclinical hypothyroidism in males was significantly more frequent in 1983–1984 vs 1999–2000 (odds ratio 5.02, 95% confidence interval 1.72–14.68; p=0.004). Salt iodization resulted in adequate UIC, decrease in serum TSH and subclinical hypothyroidism in males, and an increase in thyroid autoantibodies without significant change in thyroid abnormalities. Benefits of iodine supplementation far outweigh its hazards in Tehranian adults.

Key-words

Thyrotropin thyroid autoantibodies thyroid hormones urinary iodine goiter smoking 

References

  1. 1.
    Emami A, Shahbazi H, Sabzevari M, et al. Goiter in Iran. Am J Clin Nutr 1969, 22: 1584–8.PubMedGoogle Scholar
  2. 2.
    Azizi F, Kimiagar M, Nafarabadi M, Yassai M. Current status of iodine deficiency in the Islamic Republic of Iran. EMR Health Serv J 1990, 8: 23–7.Google Scholar
  3. 3.
    Azizi F, Sheikholeslam R, Mirmiran P. IDD Newsletter 2006 (in press)Google Scholar
  4. 4.
    Azizi F, Sheikholeslam R, Hedayati M, et al. Sustainable control of iodine deficiency in Iran: beneficial results of the implementation of the mandatory law on salt iodization. J Endocrinol Invest 2002, 25: 409–13.PubMedCrossRefGoogle Scholar
  5. 5.
    Azizi F, Rahmani M, Emami H, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed 2002, 47: 408–26.PubMedCrossRefGoogle Scholar
  6. 6.
    Sandell EB, Kolthoff IM. Micro-determination of iodine by a catalytic method. Mikrochimica Acta 1937, 1: 9–25.CrossRefGoogle Scholar
  7. 7.
    Hetzel BS. Eliminating iodine deficiency disorders-the role of the International Council in the global partnership. Bull World Health Org 2002, 80: 410–3.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Delange F. Iodine deficiency as a cause of brain damage. Postgrad Med J 2001, 77: 217–20.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Delange F, de Benoist B, Pretell E, Dunn JT. Iodine deficiency in the world: where do we stand at the turn of the century?. Thyroid 2001, 11: 437–47.PubMedCrossRefGoogle Scholar
  10. 10.
    Vitti P, Delange F, Pinchera A, Zimmermann M, Dunn JT. Europe is iodine deficient. Lancet 2003, 361: 1226.PubMedCrossRefGoogle Scholar
  11. 11.
    WHO/UNICEF/ICCIDD. Assessment of the iodine deficiency disorders and monitoring their elimination. Geneva: World Health Organization. 2001, Publication WHO/ NHD/01.1: 1–107.Google Scholar
  12. 12.
    Delange F. Risks and benefits of iodine supplementation. Lancet 1998, 351: 923–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Kahaly GJ, Dienes HP, Beyer J, Hommel G. Iodide induces thyroid autoimmunity in patients with endemic goiter: a randomized, double-blind, placebo-controlled trial. Eur J Endocrinol 1998, 139: 290–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Zois C, Stavrou I, Kalogera C, et al. High prevalence of autoimmune thyroiditis in schoolchildren after elimination of iodine deficiency in northwestern Greece. Thyroid 2003, 13: 485–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Markou KB, Georgopoulos NA, Makri M, et al. Improvement of iodine deficiency after iodine supplementation in schoolchildren of Azerbaijan was accompanied by hypo and hyperthyrotropinemia and increased title of thyroid autoantibodies. J Endocrinol Invest 2003, 26 (2 Suppl): 43–8.PubMedGoogle Scholar
  16. 16.
    Doufas AG, Mastorakos G, Chatziioannou S, et al. The predominant form of non-toxic goiter in Greece is now autoimmune thyroiditis. Eur J Endocrinol 1999, 140: 505–11.PubMedCrossRefGoogle Scholar
  17. 17.
    Azizi F, Hedayati M, Rahmani M, Sheikholeslam R, Allahverdian S, Salarkia N. Reappraisal of the risk of iodine-induced hyperthyroidism: anepidemiological population survey. J Endocrinol Invest 2005, 28: 23–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Wartofsky L, Dickey RA. Controversy in clinical endocrinology: the evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab 2005, 90: 5483–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Surks MI, Goswami G, Daniels GH. Controversy in clinical endocrinology: the thyrotropin reference range should remain unchanged. J Clin Endocrinol Metab 2005, 90: 5489–96.PubMedCrossRefGoogle Scholar
  20. 20.
    O’Leary PC, Feddema PH, Michelangeli VP, et al. Investigations of hormones and antibodies based on a community health survey: the Busselton thyroid study. Clin Endocrinol (Oxf) 2006, 64: 97–104.CrossRefGoogle Scholar
  21. 21.
    Khaleeli AA. Prevalence of thyroid antibodies in Shiraz, Iran, an area with iodine deficiency. Postgrad Med J 1981, 57: 23–7.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Belin RM, Astor BC, Powe NR, Ladenson PW. Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the Third National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2004, 89: 6077–86.PubMedCrossRefGoogle Scholar
  23. 23.
    Strieder TGA, Prummel MF, Tijssen JGP, Endert E, Wiersinga WM. Risk factors and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease. Clin Endocrinol (Oxf) 2003, 59: 396–401.CrossRefGoogle Scholar
  24. 24.
    Harrison B. Influence of cigarette smoking on disease outcome in rheumatoid arthritis. Curr Opin Rheumatol 2002, 14: 93–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Jeremy J, Mikhailidis D. Vascular and platelet eicosanoids, smoking and atherosclerosis. Adv Exp Med Biol 1990, 273: 135–46.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2007

Authors and Affiliations

  1. 1.Department of Endocrinology and MetabolismTehran University of Medical SciencesIran
  2. 2.Endocrine Research CenterShaheed Beheshti University of Medical SciencesTehranIran

Personalised recommendations